Caris Life Sciences, Inc. (CAI) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $28.48 (-0.05%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 22, 2025 | Kyle Mikson | Canaccord Genuity | $30.00 | +5.3% |
| Aug 13, 2025 | Mark Massaro | BTIG | $45.00 | +58.0% |
| Jul 13, 2025 | Subbu Nambi | Guggenheim | $32.00 | +12.4% |
Top Analysts Covering CAI
CAI vs Sector & Market
| Metric | CAI | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.26 | 2.42 |
| Analyst Count | 8 | 8 | 18 |
| Target Upside | +6.3% | +16187.2% | +19.5% |
| P/E Ratio | -452.83 | 4.21 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $256M | $262M | $266M | 4 |
| 2026-12-31 | $997M | $1.01B | $1.02B | 9 |
| 2027-03-31 | $266M | $274M | $281M | 4 |
| 2027-06-30 | $299M | $308M | $317M | 3 |
| 2027-09-30 | $306M | $315M | $324M | 3 |
| 2027-12-31 | $324M | $333M | $343M | 3 |
| 2028-03-31 | $318M | $327M | $337M | 2 |
| 2028-06-30 | $337M | $347M | $357M | 5 |
| 2028-09-30 | $346M | $356M | $366M | 4 |
| 2028-12-31 | $352M | $362M | $372M | 4 |
| 2029-12-31 | $1.65B | $1.68B | $1.71B | 5 |
| 2030-12-31 | $1.82B | $1.85B | $1.88B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.07 | $0.08 | $0.08 | 1 |
| 2026-12-31 | $0.05 | $0.15 | $0.22 | 8 |
| 2027-03-31 | $0.05 | $0.05 | $0.05 | 1 |
| 2027-06-30 | $0.09 | $0.09 | $0.10 | 1 |
| 2027-09-30 | $0.11 | $0.11 | $0.12 | 1 |
| 2027-12-31 | $0.11 | $0.12 | $0.12 | 1 |
| 2028-03-31 | $0.11 | $0.11 | $0.11 | 2 |
| 2028-06-30 | $0.12 | $0.12 | $0.12 | 2 |
| 2028-09-30 | $0.13 | $0.14 | $0.14 | 2 |
| 2028-12-31 | $0.13 | $0.14 | $0.14 | 2 |
| 2029-12-31 | $1.05 | $1.07 | $1.09 | 2 |
| 2030-12-31 | $1.13 | $1.16 | $1.19 | 5 |
Frequently Asked Questions
What is the analyst consensus for CAI?
The consensus among 8 analysts covering Caris Life Sciences, Inc. (CAI) is Buy with an average price target of $25.00.
What is the highest price target for CAI?
The highest price target for CAI is $45.00, set by Mark Massaro at BTIG on 2025-08-13.
What is the lowest price target for CAI?
The lowest price target for CAI is $30.00, set by Kyle Mikson at Canaccord Genuity on 2025-12-22.
How many analysts cover CAI?
8 analysts have issued ratings for Caris Life Sciences, Inc. in the past 12 months.
Is CAI a buy or sell right now?
Based on 8 analyst ratings, CAI has a consensus rating of Buy (2.00/5) with a +6.3% upside to the consensus target of $25.00.
What are the earnings estimates for CAI?
Analysts estimate CAI will report EPS of $0.08 for the period ending 2026-09-30, with revenue estimated at $262M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.